#ASH22: Co­gent touts da­ta on small sub­set of rare dis­ease pa­tients in bid to com­pete with Blue­print 

NEW OR­LEANS — Co­gent Bio­sciences de­liv­ered an ear­ly look at ef­fi­ca­cy and safe­ty on its ad­vanced sys­temic mas­to­cy­to­sis drug can­di­date, which the biotech hopes will …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER